ArticlePloS one2013
Robustness and backbone motif of a cancer network regulated by miR-17-92 cluster during the G1/S transition.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Regulatory RNAs in immunosenescence.Immunity, inflammation and disease · 2024Review
- Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics.Frontiers in oncology · 2021Review
- Knockdown long noncoding RNA nuclear paraspeckle assembly transcript 1 suppresses colorectal cancer through modulating miR-193a-3p/KRAS.Cancer medicine · 2019Article
- Primate-specific Long Non-coding RNAs and MicroRNAs.Genomics, proteomics & bioinformatics · 2017Review
- Dynamics and robustness of the cardiac progenitor cell induced pluripotent stem cell network during cell phenotypes transition.IET systems biology · 2017Article
- MicroRNA inhibition fine-tunes and provides robustness to the restriction point switch of the cell cycle.Scientific reports · 2016Article
- An Algorithm for Finding the Singleton Attractors and Pre-Images in Strong-Inhibition Boolean Networks.PloS one · 2016Article
- MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3.Oncology letters · 2015Article
- Review
- Stable overexpression of miR-17 enhances recombinant protein production of CHO cells.Journal of biotechnology · 2014Article
- Dynamics of random Boolean networks under fully asynchronous stochastic update based on linear representation.PloS one · 2013Article
- Boolean genetic network model for the control of C. elegans early embryonic cell cycles.Biomedical engineering online · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on interactions among transcription factors, oncogenes, tumor suppressors and microRNAs, a Boolean model of cancer network regulated by miR-17-92 cluster is constructed, and the network is associated with the control of G1/S transition in the mammalian cell cycle. The robustness properties of this regulatory network are investigated by virtue of the Boolean network theory. It is found that, during G1/S transition in the cell cycle process, the regulatory networks are robustly constructed, and the robustness property is largely preserved with respect to small perturbations to the network. By using the unique process-based approach, the structure of this network is analyzed. It is shown that the network can be decomposed into a backbone motif which provides the main biological functions, and a remaining motif which makes the regulatory system more stable. The critical role of miR-17-92 in suppressing the G1/S cell cycle checkpoint and increasing the uncontrolled proliferation of the cancer cells by targeting a genetic network of interacting proteins is displayed with our model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.